SCHEMBL28211111

SCHEMBL28211111

NC(=O)Cc1ccc(-c2ccsc2)c([N+](=O)[O-])c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.41
▸ EIF4E P06730 1/20 0.41
▸ MAPT P10636 4/20 0.37
▸ BTK Q06187 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CHEK2 O96017 2/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ IKBKB O14920 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ STAT1 P42224 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20453715 0.80 ERN1 (0.47) ERN1EIF4EMAPTALDH1A1NPSR1
SCHEMBL5913395 0.79 ERN1 (0.40) ERN1EIF4EMAPTALDH1A1SMN1; SMN2
SCHEMBL31647622 0.76 MAPT (0.47) MAPTALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL18458067 0.76 CASP6 (0.55) ERN1EIF4ECHEK2
SCHEMBL4684043 0.76 CASP6 (0.49) MAPTALDH1A1NPSR1CA2
SCHEMBL18458311 0.75 MAPT (0.48) ERN1EIF4EMAPTALDH1A1SMN1; SMN2
SCHEMBL28211106 0.74 ERN1 (0.41) ERN1EIF4EMAPTALDH1A1SMN1; SMN2
SCHEMBL15741263 0.74 S100A4 (0.47) ERN1EIF4EMAPTALDH1A1MAOB
SCHEMBL2742575 0.73 MAPT (0.58) MAPTALDH1A1SMN1; SMN2NPSR1CA2
SCHEMBL10665444 0.73 TSHR (0.54) MAPTALDH1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922375-A Target the antitumoral compounds and its application method of IDH2 mutation 正大天晴药业集团股份有限公司 2018-04-17 — — CN disclosed
Send feedback